Beta-2 Agonist Compounds with Extended Duration and Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current betamimetic drugs for treating inflammatory and obstructive respiratory complaints have short durations of activity, requiring frequent administration and lacking selectivity for β2-adreno-receptors, which complicates patient adherence and therapeutic efficacy.
Innovation Solution
Development of compounds of formula 1, specifically designed to have a longer duration of action and high selectivity for β2-adreno-receptors, allowing for once-daily administration as a pharmaceutical composition for treating inflammatory and obstructive respiratory complaints.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional betamimetic drugs are used, then therapeutic effect is achieved, but duration of activity is short requiring frequent administration
Solution Approach 1:
The patent modifies the chemical structure of betamimetic drugs by changing parameters such as introducing specific side chains (e.g., arylalkyl, cycloalkylalkyl groups) and modifying the core scaffold (e.g., using 1,2,4-triazole derivatives instead of conventional amine structures). These structural parameter changes result in compounds with prolonged half-life and extended duration of action, enabling once-daily administration while maintaining therapeutic efficacy.
2Reliability
If conventional betamimetic drugs are used, then respiratory complaints are treated, but selectivity for β2-adreno-receptors is insufficient
Solution Approach 1:
The patent applies local quality by introducing specific functional groups and structural features at particular positions in the molecular structure. For example, the 1,2,4-triazole ring system with specific substituents (aryl groups at position 5, alkyl groups at position 1) creates localized chemical properties that enhance β2-adreno-receptor binding affinity and selectivity, thereby reducing off-target effects while maintaining therapeutic effectiveness.
3Reliability
If frequent administration is required, then therapeutic effect is maintained, but patient adherence is compromised
Solution Approach 1:
The patent achieves continuity of useful action by designing compounds with extended half-life characteristics. The modified molecular structures (e.g., with bulky side chains and rigid cores) provide more stable pharmacokinetic profiles, ensuring continuous therapeutic effect throughout the dosing interval. This eliminates the need for frequent dosing while maintaining reliable therapeutic efficacy, thereby improving patient adherence and quality of life.
Data Source
AI summary
A compound of formula 1wherein the groups R1, R2, R3, R4 and n may have the meanings given in the claims and in the specification, and methods for preparing a pharmaceutical composition for the treatment of inflammatory and obstructive respiratory complaints.